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The cancer immunoediting hypothesis postulates a dual role of the immune system: pro-
tecting the host by eliminating tumor cells, and shaping the tumor by editing its genome.
Here, we elucidate the impact of evolutionary and immune-related forces on editing the
tumor in a mouse model for hypermutated and microsatellite-instable colorectal cancer.
Analyses of wild-type and immunodeficient RAG1 knockout mice transplanted with MC38
cells reveal that upregulation of checkpoint molecules and infiltration by Tregs are the major
tumor escape mechanisms. Our results show that the effects of immunoediting are weak and
that neutral accumulation of mutations dominates. Targeting the PD-1/PD-L1 pathway using
immune checkpoint blocker effectively potentiates immunoediting. The immunoediting
effects are less pronounced in the CT26 cell line, a non-hypermutated/microsatellite-instable
model. Our study demonstrates that neutral evolution is another force that contributes to
sculpting the tumor and that checkpoint blockade effectively enforces T-cell-dependent
immunoselective pressure.
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The concept of cancer immunosurveillance, i.e., thatlymphocytes can recognize and eliminate tumor cells, wasproposed almost 50 years ago1. The definitive work
supporting the existence of this process was published 30 years
later by the Schreiber lab2. In this seminal work, an elegant
experiment was carried out using a mouse model lacking the
recombination activating gene 2 (RAG2), which encodes a pro-
tein involved in the initiation of V(D)J recombination during B-
and T-cell development. RAG2-deficient mice, which are viable
but fail to produce mature B or T lymphocytes3, developed sar-
comas more rapidly and with greater frequency than genetically
matched wild-type controls2. Moreover, tumors derived from
those mice were more immunogenic than those from wild-type
mice2. These findings led to the development of the refined
cancer immunosurveillance concept: the cancer immunoediting
hypothesis4. The cancer immunoediting postulates a dual role of
the immunity in the complex interactions between tumor and
host; the immune system, by recognizing tumor-specific antigens,
not only protects the host through elimination of tumor cells, but
can also sculpt the developing tumor by editing the cancer gen-
ome, thereby producing variants with reduced immunogenicity.
Cancer immunoediting is more difficult to study in humans,
but clinical data from patients with severe immunodeficiencies is
supporting the notion that this process also exists in humans5.
Indirect evidence for the existence of immunoediting in some
cancers was provided by calculating the ratio of observed and
predicted neoantigens, i.e., tumor antigens derived from mutated
proteins6. Using a similar approach, we recently provided addi-
tional data supporting the existence of immunoediting in
microsatellite-instable (MSI) colorectal cancer (CRC)7. However,
as we recently showed in a pan-cancer genomic analysis, the
composition of the intratumoral immune infiltrates is highly
heterogeneous and changing during tumor progression8 and
hinders the distinction of genetic, immune, and other evasion
mechanisms. Over and above these mechanistic questions on
tumor progression, there is an urgent need to investigate cancer
immunoediting also in the context of cancer immunotherapy.
Cancer immunotherapy with checkpoint inhibitors like anti-
CTLA-4 or anti-PD-1/-PD-L1 antibodies are showing remarkable
clinical responses9. However, one of the biggest challenges is
intrinsic resistance to immunotherapy and the development of
resistant disease after therapy, i.e., acquired resistance to
immunotherapy. As many patients with advanced cancers are
now receiving immunotherapy, elucidating the role of cancer
immunoediting as a potential mechanism of acquired resistance
to immunotherapy10 is of utmost importance.
Surprisingly, despite the recognition of the cancer immunoe-
diting process and the widespread use of both mouse models and
next-generation sequencing (NGS) technologies, the impact of
immunoediting on the cancer genome has not been well char-
acterized. Cancer immunoediting was investigated in a mouse
model of sarcoma using NGS of the tumor exome and algorithms
for predicting neoantigens11. This sarcoma model showed that
immunoediting can produce tumor cells that lack tumor-specific
rejection antigens, but how this finding translates into common
human malignancies remained unclear. Later, two widely used
tumor models, a CRC cell line MC38 and a prostate cancer cell
line TRAMP-C1, were used to identify immunogenic tumor
mutations by combining NGS and mass spectrometry12. However,
as neither longitudinal samples of wild-type or immunodeficient
mice nor checkpoint blockade was applied, two major questions
remain unanswered: (1) To what extent is T-cell-dependent
immunoselection sculpting the cancer genome? (2) How is
immunotherapy with checkpoint blockers modulating immunoe-
diting? Quantitative evaluation of immunoediting during tumor
progression, as well as following therapeutic intervention using
checkpoint blockers could not only provide novel mechanistic
insights, but might also inform immunotherapeutic strategies that
could potentially be translated into the clinic.
We therefore designed a study to investigate immunoediting of
an epithelial cancer genome using wild-type and immunodefi-
cient mice, NGS, and analytical pipelines to process and analyze
the data. We first characterize the genomic and transcriptomic
landscape of the mouse colon adenocarcinoma cell line MC38
(mouse colon #38) that was induced by the subcutaneous injec-
tion of dimethylhydrazine in C57Bl/6 mice13, and show that this
cell line is a valid model for hypermutated/MSI CRC. We then
carry out experiments with wild-type and immunodeficient
RAG1−/− mice with transplanted tumors and analyze longitudinal
samples with respect to the genomic landscape and the immu-
nophenotypes of the tumors. The results show the extent of
immunoediting of the cancer genome in this model in relation to
other selection processes. Finally, we perform experiments with
anti-PD-L1 antibodies using the MC38 cell line and another CRC
cell line which is a model for non-hypermutated/MSI- CRC
(CT26 (Colon Tumor #26)) and show how targeting the PD-1/
PD-L1 pathway modulates immunoediting.
Results
Immunogenomic and transcriptomic characterization of
MC38 cell line. Functional studies on immunoediting require
genetic tools and controls afforded by mouse studies. As immu-
noediting has not been quantified using mouse epithelial cancers
so far, we designed experiments with transplanted tumors using
the murine MC38 cell line. The MC38 murine CRC cell line is
derived from a grade-III adenocarcinoma that was chemically
induced in a female C57BL/6 mouse and used since then as a
transplantable mouse tumor model14. Several studies have shown
that the cell line is immunogenic and can be used as a model for
investigating anticancer immunity and immunotherapy15–18. To
characterize the genome and transcriptome of the MC38 cell line,
we performed whole-exome sequencing, SNP array analysis, and
RNA sequencing (Fig. 1a). We identified 5931 somatic mutations
of which 2743 were nonsynonymous (2585 missense, 158 stop-
gained) and 354 indels (Fig. 1b). Of the 5931 SNVs, the majority
(4775) were transversions, of which most (2759) were C>A/G>
T. Human hypermutated CRC tumors containing POLE
mutations showed increased proportions of C>A/G> T and
T>G/A> C transversions19,20. In contrast, it has been shown
that the mouse CT26 cell line shows predominantly C> T/G>A
SNVs21, similar to primary human non-hypermutated CRC
tumors22. Analysis of the MC38 data using previously published
mutational signatures19 revealed a mutational profile consisting
of a combination of signatures, including the signature for DNA
mismatch-repair (MMR) deficiency (Supplementary Figure 1).
We investigated whether known CRC driver mutations are also
present in MC38. We found missense mutations in TP53, PTEN,
and mutations in the tumor growth factor (TGF) beta pathway
(SMAD2, SMAD4, ACVR2A, TGFB2, but not TGFBR2). BRAF
was also mutated, which is frequently associated with the MSI-
high phenotype23. KRAS was not mutated and there was only one
intron mutation in APC. However, there was a truncating
mutation in AXIN2 which is known to regulate β-catenin in the
Wnt signaling pathway. The frequent mutations in SOX9 and
ARID1A22 were also present in the MC38 cell line. SOX9 is a
transcription factor that inhibits Wnt signaling24 and has a role in
regulating cell differentiation in the intestinal stem cell niche25,
whereas ARID1A is involved in suppressing MYC transcrip-
tion26. Four driver mutations of the MC38 cell line correspond to
known hotspots in human CRC, albeit at different positions27
(Supplementary Data 1).
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In a previous large-scale genomic study of human colorectal
samples three subtypes of colorectal cancer were identified22: (1)
microsatellite stable tumors (MSS), (2) tumors with MSI due to a
DNA MMR system deficiency, and (3) hypermutated tumors that
harbor mutations in the exonuclease (proofreading) domain of
the DNA polymerases Pol δ (POLD1) and Pol ε (POLE).
The MC38 data also showed mutations in the MMR gene
MSH3, as well as in POLD1, indicating that the MC38 cell line is
a valid model to study human MSI and hypermutated CRC. Both
MSI and hypermutated CRC were reported to have better
prognosis, higher infiltration of CD8+ T cells and respond well to
checkpoint blockade therapy28, likely due to the high number of
neoantigens.
We then characterized copy number variants of the MC38 cell
line using exome sequencing and SNP arrays. The analysis of the
copy number profiles inferred from the exome-sequencing data
using hidden Markov model algorithm (see Methods) and from
the SNP array data were concordant and showed a mostly diploid
genome, with some regions of amplifications and deletions
(Fig. 1a). We identified amplifications in the regions that contain
the MYC and ERBB2 genes. Finally, we carried out transcrip-
tomic analysis of the MC38 cell line in comparison with normal
skin tissue. The transcriptomic data were used to: (1) identify
pathways that were up- or downregulated in the cell line, and (2)
to identify expressed tumor antigens, including neoantigens
(identified using exome-sequencing data and a prediction
algorithm as previously described29) and cancer-germline anti-
gens (CGAs). The latter are tumor antigens that are considered to
be tumor-specific as these molecules are expressed only in
germline cells and in tumor cells. Pathway enrichment analysis
identified pathways related to cell cycle, DNA replication, DNA
repair, and metabolism of nucleotides (Supplementary Figure 2).
With respect to the tumor antigens, we identified a large
number of expressed neoantigens (Fig. 1c) and expressed CGAs
(Fig. 1d), which provide evidence for the immunogenicity of this
model. Of the 2743 amino-acid changes (missense and stop
codon) in MC38, 1399 neoantigens were predicted to strongly
bind to the C57Bl/6 major histocompatibility molecules (MHC)
class I molecules H2-Kb and H2-Db with < 500 nM, and of these,
489 were in expressed genes. In addition, several CGAs were
highly expressed in MC38 including TAD2, RQCD1, SPAG9,
PBK, CTAGE5, CASC5, and CEP55, which were also found to be
expressed in the CT26 cell line21. It is noteworthy that these
CGAs were also expressed in the skin samples.
Thus, the characterization of the genomic and transcriptomic
landscape of the CRC MC38 cell line demonstrates its validity as a
model for hypermutated and/or MSI colorectal cancer.
Upregulating checkpoints is a tumor escape mechanism in
MC38 cell line. In our mouse model used to recapitulate the
process of cancer immunoediting, MC38 cells were sub-
cutaneously injected into wild-type C57Bl/6 and immunodeficient
RAG1−/− mice. The tumor growth was monitored regularly and
samples were collected at predefined time points and subjected to
detailed analysis using FACS, exome and RNA sequencing, and
SNP array analysis (Fig. 2a). As expected, the tumor growth was
significantly faster (two-tailed unpaired Student’s t-test, p-value of
0.019) in RAG1−/− mice compared with the wild-type mice
(Fig. 2b).
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Fig. 1 Immunogenomic and transcriptomic characterization of the mouse MC38 cell line. a Circos plot showing (outer to inner): cytogenetic bands in black,
gray, and white. Track 1: DNA copy number log ratio values. Dark gray: diploid; Red: amplification (log ratio> 0.25); Blue: deletion (log ratio< −0.25). Track
2: Point mutations, plotted based on the variant allele frequency. Inner is frequency 0, outer is 100. Colors are purple (0–40), green (40–60), yellow
(60–80), and pink (80–100). Track 3: Predicted MHC binding IC50 scores for the nonsynonymous mutations. Mutations with the highest binding affinity
are colored orange (IC50< 50). Track 4: insertions and deletions colored according to their allele frequency. b Number of mutations in MC38 classified by
type. c Number of predicted and expressed neoantigens in MC38. d Known germline antigens with the highest expression in MC38. The expression values
are in normalized counts
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FACS analysis revealed infiltration of both innate and adaptive
immune cells including CD8+ T cells, (natural killer) NK cells,
and classically activated (M1) macrophages in wild-type mice,
that increased with time, although not significantly (Fig. 2c). RNA
expression profiles revealed higher expression of chemoattractant
molecules such as CXCL9 and CCL5 in wild-type mice in
comparison with immunodeficient mice (Supplementary Fig-
ure 3). However, despite the presence of tumor-infiltrating
lymphocytes in the slow-growing tumors, the adaptive immune
system failed to eliminate the tumors. Tumors may utilize several
mechanisms of escape such as antigen loss, upregulation of
inhibitory molecules, downregulation of MHC, or establishment
of an immunosuppressive environment. The CD8/Treg cell ratio,
which is a surrogate marker for a suppressive tumor micro-
environment, was higher in the skin samples compared with the
tumor samples at day 23 (Fig. 2c), suggesting that one escape
mechanism in this model is the presence of immunosuppressive
cells. The number of myeloid-derived suppressive cells and Tregs
were comparable in both time points in wild-type mice, whereas
the alternatively activated (M2) macrophages were significantly
reduced (two-tailed unpaired Student’s t-test, p-value of 0.009).
The tumor progression in wild-type samples was associated with
upregulation of immunoinhibitory genes, including PD-1, CTLA-
4, TIM3, and LAG3 (Supplementary Figure 4). MC38 cells
expressed low levels of PD-L1, whereas PD-L1 was slightly
upregulated in RAG1−/− and more in wild-type mice. Our finding
is in accordance with previous studies showing that PD-L1
expression of MC38-transplanted tumors increases as a result of
exposure to inflammatory cytokines such as interferon gamma
(IFNγ), which is sufficient for tumor escape and immune
evasion30,31. The upregulation of PD-L1 is likely due to the
phenotypic plasticity and not positive selection of high PD-L1
clones. Pathway analysis of the differentially expressed genes in
wild-type vs RAG1−/− tumors showed upregulation of several
immune processes related to activation of an adaptive immune
system response such as costimulation by CD28, PD-1 signaling,
antigen processing and presentation, NK cell-mediated cytotoxi-
city, TCR signaling and IFNγ signaling (Fig. 2d and Supplemen-
tary Figure 5a) Downregulated pathways and GO terms included
processes related to cell cycle, DNA replication, and TNF
signaling (Supplementary Figure 5b).
These data indicate that two tumor escape mechanisms are
activated in this model: infiltration of immunosuppressive Tregs
and upregulation of inhibitory genes.
Neutral evolution outweighs immunoselection. Tumor pro-
gression is an evolutionary process under Darwinian selection32, a
characteristic that has been attributed as the primary reason of
therapeutic failure, but also as a feature that holds the key to more
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Fig. 2 Tumor progression and tumor-infiltrating immune cells in wild-type and RAG1−/− mice. a Schematic diagram of the experimental setup. b Tumor
growth curves of 5 × 104 MC38 cells inoculated into C57Bl/6 wild-type (n= 10) and RAG1−/− mice (n= 4). c Tumor-infiltrating lymphocytes in wild-type
and RAG1−/− mice analyzed by flow cytometry. b, c The data are presented as the mean± SEM, analyzed by a two-tailed unpaired Student’s t-test. Statistical
significance is indicated as *p< 0.05, ** p< 0.01, *** p< 0.001. d Enriched functions and pathways of the significantly differentially expressed genes in
tumors of the wild-type vs RAG1−/− mice taken at day 23. The network is created using ClueGO. The pathways are functionally grouped based on the kappa
score and the most significant term of each group is highlighted. The size of the nodes shows the enrichment significance after Bonferroni correction
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effective tumor control. At the time of detection, a tumor has
acquired novel somatic mutations of which only a small subset
(called driver mutations) provide an evolutionary advantage. The
immune system also exerts an evolutionary pressure, through a
T-cell-dependent immunoselection process by acting on tumor
clones that display strong rejection antigens11, and to some extent
by T-cell-independent immunoselection through M1 macro-
phages, IFNγ, and NK cells33. In addition to the ongoing evolu-
tionary and immune-related clonal selection, a recent study using
a theoretical model demonstrated the occurrence of neutral
evolution during tumor development34. According to this model,
tumor heterogeneity in some cancers, including CRC, can be
explained by neutral expansion and the accumulation of pas-
senger mutations without selective sweeps.
To elucidate the impact of immunoselection on the progressing
tumor, we used exome sequencing to identify nonsynonymous
mutations and a MHC class I binding algorithm to predict
candidate neoantigens. The number of shared mutations was
similar between the biological replicates, suggesting that the
sampling bias is rather small (Supplementary Figures 7 and 8).
Further analysis of the exome-sequencing data showed a high
number of mutations that were shared between the MC38 cell
line and the two consecutive time points in both, wild-type (2299)
and RAG1−/− (2372) samples (Fig. 3a).
According to the cancer immunoediting hypothesis, the immune
system can sculpt the developing tumor by editing the cancer
genome, thereby modifying the heterogeneity of the tumor: strong
immunoediting would render tumors more homogeneous by
eradicating immunogenic clones. In order to analyze the hetero-
geneity of the tumors during progression, exome-sequencing data
and SNP array data was used to estimate cancer cell fractions
(CCF) of all point mutations and, subsequently, tumor hetero-
geneity. Analyses of the tumor heterogeneity did not reveal large
differences during progression in both, wild-type and RAG1−/−
samples (Fig. 3b). Strikingly, the analyses showed that the variant
allele frequencies (VAF) of the majority of the mutations did not
change with time in both the wild-type and in the RAG1−/− mouse.
On average, 3–5% of the mutations in the wild-type and in the
RAG1−/− samples did not change their VAF (Supplementary
Table 1) suggesting that neutral evolution, rather than Darwinian
evolution, is driving the tumor growth in this model.
We then characterized the neoantigens using exome-
sequencing data (to derive somatic mutations), RNA-
sequencing data (for filtering expressed mutations) and an
algorithm for predicting peptide-MHC binding affinity (see
Methods). In order to identify immunogenic mutations, we
selected the expressed neoantigens with the highest binding
affinity (IC50< 500 nM). In a previous study with the MC38 cell
line, seven mutant peptides were identified, using mass spectro-
metry, of which two elicited a T-cell response12. In our analysis,
five out the seven peptides were predicted and four of them were
detectable from the RNA expression data (Fig. 3c) The large
impact of neutral evolution was evident also in the Venn
diagrams of the number of neoantigens (Fig. 3d). The number of
identified newly generated neoantigens was comparable in all
samples (75 and 66 for the wild-type samples at day 23 and 46)
and was higher than the potentially lost or targeted neoantigens
(31 and 24 in the wild-type samples). As the key value to
understand immunoediting is the ratio between expressed
neoantigens and total number of mutations, we calculated these
values, and show that the ratio was similar across all samples
(Supplementary Figure 5a). Finally, to exclude the possibility that
clones may have lost neoantigen-generating mutations, we
determined the degree of loss of heterozygosity (LOH) in the
samples. Although the number of events increased in the
transplanted tumors in wild-type and in immunodeficient mice
(Supplementary Figure 5b), there were no LOH events at the
genomic positions of the neoantigens, suggesting that no
neoantigens were lost owing to LOH.
We then focused our analysis on the tumor samples taken at
the same time point, day 23, for wild-type and RAG1−/− samples
and considered neoantigens found both in the MC38 cell line and
in at least one of the RAG1−/− tumors (Fig. 3e). There were 409
neoantigens shared by the wild-type and RAG1−/− tumors, and
the MC38 cell line samples. About 6% of the neoantigens (23 out
of 409) were detectable only in RAG1−/− tumors (Supplementary
Data 2), out of which 21 were derived from mutations not
detected or eliminated in the wild-type tumors. Only two
neoantigens were lost because of low expression. The small
number of lost neoantigens imply that the impact of the T-cell-
dependent immunoediting in this model is rather modest. In
addition, a similar number of neoantigens (14) was detectable
only in wild-type tumors, suggesting that these neoantigens were
edited by T-cell-independent mechanisms. Upregulation of genes
related to NK cell-mediated toxicity and IFN signaling further
supports this observation (Supplementary Figure 6a). Analysis of
the downregulated transcripts revealed genes related to DNA
replication and cell cycle (Supplementary Figure 6b).
Heterogeneity analysis showed that all MC38-derived tumors
as well as the MC38 cell line, were similarly heterogeneous
(Fig. 3f, g). To infer how the clonal composition changes between
samples, we used a Bayesian Dirichlet process to cluster clonal
and subclonal mutations. The results showed that the clonal and
subclonal clusters were on the leading diagonal of the plots
indicating there was no change in the mutational profile and the
clonal/subclonal composition between any two samples (Fig. 3f).
There was a large percentage of clonal mutations (60–70%) both
in the MC38 and in the individual tumor samples (Fig. 3h and
Supplementary Figures 7, 8). This was evident also from the VAF
plots of the mutations found in diploid regions (Supplementary
Figure 9).
Overall, the results suggest that the clonal dynamics of this
cancer cell line over time is not dominated by strong Darwinian
selection, but rather follows neutral evolution.
Targeting the PD-1/PD-L1 pathway potentiates immunoedit-
ing. By targeting the PD-1/PD-L1 axis to generate a strong
immunological pressure, we next investigated the resulting
impact on the cancer genome, on the neoantigen landscape, and
on the tumor heterogeneity. It was previously shown that MC38
responds to various immunotherapies16,18,35,36. In order to
identify neoantigens that would be potential targets of T cells
activated by checkpoint blockade therapy, wild-type C57Bl/6
mice were treated with anti PD-L1 antibodies or IgG2b antibodies
as control. Treatment was started 1 day after tumor inoculation
and then repeated every 3–4 days. Samples from six tumors
treated with anti-PD-L1 and six tumors treated with IgG2b were
taken on day 14. Three samples of each group were used for
exome sequencing, and three for RNA-sequencing.
Treatment with anti-PD-L1 antibodies reduced tumor growth
in the treated mice compared with the controls by 65% (Fig. 4a),
which is in line with previous studies showing that MC38
responds well to PD-1/PD-L1 blockade therapy37,38. This was
further reflected in the RNA-sequencing data, which showed a
strong upregulation of IFNγ, perforin, and granzyme A and B
(GZMA and GZMB), as well as different immunomodulators and
MHC molecules (Supplementary Figure 10). GO and pathway
analysis showed upregulation of immune-related processes such
as PD-1 signaling, chemokine signaling, cytokine-cytokine
receptor interaction, and NK cell-mediated cytotoxicity (Fig. 4b
and Supplementary Figure 11). Hence, blocking of the PD-1/PD-
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percentiles
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02424-0
6 NATURE COMMUNICATIONS |  (2018) 9:32 |DOI: 10.1038/s41467-017-02424-0 |www.nature.com/naturecommunications
L1 pathway induces very strong adaptive, and to a lesser extent
innate, -mediated antitumor activity in this mouse model.
Analysis of the exome-sequencing data showed 902 mutations
that were shared in all samples and 617 mutations that were
detectable in the control sample and in the MC38 cell line, but
absent from the anti-PD-L1-treated samples (Fig. 4c). These
mutations are potentially targeted by the immune system
following blockade of the PD-1/PD-L1 pathway. A smaller
number of mutations were detectable only in the anti-PD-L1-
treated samples and the MC38 cell line (50). Overall, in the anti-
PD-L1-treated samples the fraction of mutations resulting in
expressed antigens was similar to the control sample (~25%). The
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ratio of expressed neoantigens and total number of mutations was
highest in the anti-PD-L1-treated sample (Supplementary
Figure 13). Analysis of the peptides did not show any obvious
pattern that could pinpoint rules defining the immunogenicity of
the mutations (Supplementary Data 3).
A major shift was observed in the fraction of expressed
neoantigens of clonal origin in both, anti-PD-L1 and control
treated samples (Fig. 4d and Figure 13). The fraction of clonal
neoantigens was 60, 95, and 93% in the MC38, anti-PD-L1
treated, and the control tumors, respectively. Tumor hetero-
geneity analysis revealed more homogenous tumors undergoing
treatment with checkpoint blockers compared with the control
tumors and the MC38 cell line (Fig. 4e). The same pattern can be
observed in the 2D density plots, which show a shift of subclonal
mutations in MC38 toward clonality in the anti-PD-L1 samples
(Fig. 4f), suggesting negative selection of immunogenic subclones.
In addition, we investigated the effect of targeting the PD-1/
PD-L1 axis on the cancer genome using another widely used CRC
cell line, CT26. Previous genomic characterization of this cell line
showed mutation in KRAS and lack of mutations in MMR,
POLD1/POLE, and BRAF genes, suggesting that this cell line is a
better model for non-hypermutated/MSS human CRC tumors22.
From the 1172 point mutations in expressed genes in the CT26
cell line, 154 were in epitopes predicted to strongly bind to MHC
molecules22, showing that the neoantigen burden is about 73%
lower compared with MC38 cell line.
Treatment with anti-PD-L1 antibodies reduced tumor growth
in the treated mice by 50% compared with the controls
(Supplementary Figure 14a), indicating that this model is less
sensitive to immunotherapy with PD-L1 blockers compared with
the MC38 cell line. Our results are in line with a recent study
showing that tumor growth inhibition following treatment with
anti-PD-L1 blocking antibodies was twice as efficient in mice
transplanted with MC38 cells compared with mice transplanted
with CT26 cells31. Analysis of the exome-sequencing data showed
a large fraction of mutations that were shared in all samples (848)
and 94 mutations that were not detectable in the anti-PD-L1-
treated samples and therefore likely to have been targeted by the
immune system (Supplementary Figure 15b). A similar number
of mutations was detectable only in the anti-PD-L1-treated
samples and the CT26 cell line (60) Thus, the fraction of
immunoedited mutations compared with all mutations in the
CT26 model was sixfold smaller than in the MC38 model,
confirming that the CT26 cell line is less immunogenic than the
MC38 model.
Similar to the MC38 cell line, there was a decrease in the
number of neoantigens from subclonal origin in the anti-PD-L1-
treated sample, albeit less pronounced (Supplementary Figure 14c,
15). The ratio of neoantigens and total number of mutations was
slightly higher in the transplanted samples (Supplementary
Figure 15d). There was no overlap of the peptides between the
CT26 (Supplementary Data 4) and the MC38 model. The tumor
heterogeneity of the anti-PD-L1 and the control samples were
comparable (Supplementary Figure 14e) as would be expected by
the similar numbers of targeted mutations (33 vs. 41). Finally,
there was no detectable shift of subclonal mutations in CT26
toward clonality in the anti-PD-L1 samples.
Overall, the analyses of this experimental data suggest that
targeting the PD-1/PD-L1 pathway potentiates immunoediting
and changes the evolutionary dynamics from neutral to non-
neutral in the MC38 model of hypermutated/MSI CRC. More-
over, this immunotherapeutic intervention renders the tumors
more homogeneous, which could possibly explain the develop-
ment of resistance to checkpoint blockers. The immunoediting
effects were less pronounced in the CT26 model, likely owing to
the less-immunogenic nature of this model.
Immunoediting and acquired resistance to PD-1 blockade. In
order to test the relevance of our findings in human cancer, we
analyzed genomic data from a recent study of acquired resistance
to PD-1 blockade in melanoma39. In this work, pretreatment and
relapse samples from four patients with metastatic melanoma,
which were subjected to anti PD-1 blockade therapy, were ana-
lyzed by exome sequencing. Sequencing data showed that two of
the tumors developed loss-of-function mutations in JAK1 and
JAK2, respectively, which resulted in lack of response to IFNγ.
The third tumor had a mutation in the antigen-presenting protein
β2M, which prevented the immune system from recognizing the
tumor, whereas the fourth tumor had no defined mutations,
which could be associated with the relapse39.
Using exome-sequencing data, we analyzed the samples taken
before therapy and after relapse with respect to the changes in the
mutational landscape, the tumor heterogeneity and the clonal
architecture. As can be seen in Fig. 5a, a large fraction of the
mutations was detectable in baseline samples and in the relapse
samples in all four cases, implicating that the bulk of the
mutations were not efficiently targeted. Newly generated muta-
tions ranged between 5% (case 1) and 33% (case 2). Mutations
that were potentially immunoedited following PD-1 blockade, i.e.,
mutations detectable only in the baseline samples ranged between
4% (case 2) and 58% (case 3). Specifically, case 3 appeared to have
strong immunoediting effects on the cancer genome.
With respect to the tumor heterogeneity, targeting the PD-1/
PD-L1 pathway showed a similar trend: relapsed tumors that
acquired larger number of mutations became more heterogeneous
(case 2 and case 4), whereas the tumor with lower number of
acquired mutations became more homogeneous (case 3) (Fig. 5b).
The analysis for case 1 did not reveal changes in the tumor
heterogeneity likely owing to the high number of mutations in
both, baseline and relapse sample (1045). Thus, in this case the
impact of newly generated mutations on the tumor heterogeneity
is rather small. The analyses of the clonal architecture revealed
that in all tumors there was a loss of clonal mutations in the
relapsed samples compared with the baseline, ranging from 1%
(Case 2) to 24% (Case 3) (Fig. 5c). Tumors that became more
heterogeneous had an increased number of subclonal mutations
compared with the baseline (case 2 and case 4). In accordance
with the immunoediting hypothesis, the relapsed sample showing
a strong immunoediting effect (case 3) had the largest decrease of
both, clonal and subclonal mutations, and hence, was more
homogeneous.
Overall, these results indicate that immunoediting can be
associated with acquired resistance to PD-1 blockade in
melanoma in some tumors with specific mutational phenotypes.
Targeting the PD-1 pathways in these phenotypes seems to
broaden the T-cell repertoire in a way that both, clonal and
subclonal mutations, are targeted and subsequently render the
tumor more homogeneous. Hence, a clone that is resistant to
immune attack will ultimately dominate the population. How-
ever, given the small number of cases and the variability of the
results, further studies will be necessary to investigate the effects
of the checkpoint blockade on the tumor heterogeneity in
relapsed tumors and confirm our findings.
Discussion
With the development of immunotherapies with checkpoint
blockers as well as other immunotherapeutic strategies, including
therapeutic vaccines and engineered T cells40, the interaction of
the tumor and the immune system, and the question of how the
cancer genome is edited came into focus. Our understanding of
the process of cancer immunoediting and its relevance for ther-
apeutic intervention is still incomplete and requires
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comprehensive genomic analyses of longitudinal samples. Here
we characterized, for the first time, the extent of immunoediting
that tumors undergo during progression or as a consequence of
the targeting the PD-1/PD-L1 axis. The quantification of cancer
immunoediting using a mouse model of a common cancer sug-
gests several biological conclusions and has also important
implications for clinical translation.
First, neutral evolution outweighs the effects of T-cell-
dependent and T-cell-independent immunoselection on the
cancer genome during tumor progression in the MC38 model of
hypermutated/MSI CRC tumors. Neutral tumor evolution was
only recently identified, using a theoretical model that determines
the expected distribution of subclonal mutations, and implies that
a large number of new mutations are generated in ever smaller
subclones, resulting in many passenger mutations that are
responsible for intratumoral heterogeneity, but have minimal or
no impact on tumor expansion34. In this neutral evolution model
all the mutations responsible for expansion are present in the
founding cell and subsequent mutations are neutral. Analysis of
the TCGA data showed that CRC and some other cancers were
dominated by neutral evolution whereas other cancers were not34.
It should be noted that there are three major evolutionary forces
that influence tumor progression and can shape the clonal tra-
jectory of the tumors in this experimental setting: (1) drift owing
to sampling bias of the transplants, (2) positive selection for
engraftment, and (3) negative selection by the immune system.
Drift can be due to random sampling of few related clones from
the initial population, and would have the effect of increasing the
number of the clonal composition of the transplanted tumors.
The same effect would be observed in the scenario of positive
selection for engraftment because of selection of clones that are
able to survive transplantation. Our analyses show that the
majority of the new mutations in the transplanted tumors, both in
wild-type and immunodeficient mice are subclonal, suggesting
that the effects of random drift and selection due to transplan-
tation are negligible. Last, we provide three lines of evidence that
the contribution of the negative selection by the immune system
is small: (1) the ratio between the expressed neoantigens and the
total number of mutations did not change between different
samples; (2) although the number of LOH events was increased in
the transplanted tumors (both in wild-type and in immunodefi-
cient mice), there were no LOH events at the genomic positions
of the neoantigen-deriving mutations, suggesting that no
neoantigens are lost due to LOH; and (3) there was no loss of
expression of the shared neoantigens. Collectively, these data
support the neutral evolution model in the MC38 model of
hypermutated/MSI CRC tumors.
Second, targeting the PD-1/PD-L1 pathway effectively
potentiates immunoediting and changes the dynamics of the
system from neutral to non-neutral in the MC38 model. Cur-
rently, we can only speculate on the underlying mechanisms
driving the strong immune response. It has been previously
shown that immunotherapy with anti-CTLA-4 antibodies leads to
a significant number of newly detected T-cell responses41, which
can be assigned to broadening of the T-cell receptor (TCR)
repertoire42. Our data support this model in terms of therapeutic
strategy blocking the PD-1/PD-L1 axis. The broadening of the
TCR repertoire might be one of the mechanisms of action of anti-
PD-1 treatment and could explain the success of immunotherapy
in a number of malignancies. As CTLA-4 and PD-1 have differing
immunological effects on circulating T cells, further mouse and
human studies are necessary in order to test the hypothesis that
the expansion of the TCR repertoire is a mechanism that
potentiates immunoediting also in a therapeutic strategy that
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blocks the PD-1/PD-L1 axis. Notably, targeting the PD-1/PD-L1
pathway in a less-immunogenic model, CT26, resulted in fivefold
smaller immunoediting, and consequently less-pronounced
effects on the cancer genome. Intriguingly, similar genotype-
immune response associations are observed in humans CRC
tumors: MSI tumors respond to checkpoint blockade, whereas
MSS are refractory28. Further studies are necessary to investigate
these genotype-immunophenotype relationships and pinpoint
genetic drivers of immunoediting, and ultimately provide possible
explanation for the resistance to immune checkpoint blockers in
MSS patients despite the fact that tumor-infiltrating lymphocytes
represent a strong independent predictor of relapse and survival7.
And third, targeting the PD-1/PD-L1 pathway renders the
tumors more homogeneous in the MC38 model. Although we did
not carry out long-term experiments with different dosages and
treatment schedules, one implication of this result is that the
tumors might eventually become resistant to immunotherapy. We
also provide data from a human study showing that in some cases
tumors that relapse after PD-1 blockade are more homogeneous.
Hence, cancer immunoediting could represents one mechanism
of acquired immunotherapy resistance in specific mutational
phenotypes. However, other mechanisms like epitope spreading43
(immune responses to secondary epitopes) and immunodomi-
nance44 (dominant epitopes can mask subdominant ones) could
counterbalance or ameliorate this effect and thereby determine
whether the tumor is eradicated or not.
On the cautionary side, the model we have used has certain
limitations since it is based on a cell line, which has been edited
and it does not recapitulate evolution of the tumor as it occurs
naturally. However, as shown by others12 and in this study, the
MC38 model is immunogenic and responds to treatment with
immune checkpoint blockers, suggesting that the MC38 cell line
has evolved and acquired mutations that can be detected by the
immune system. Moreover, the resemblance of the MC38 and the
CT26 models to the clinical observations of the response of CRC
patients treated with immune checkpoint blockers further sup-
ports the relevance of the chosen model. More sophisticated
approaches using CRISPR/Cas9 technology for introducing
mutations that drive spontaneous rejection of the tumor could
provide additional insights into the complex evolutionary
dynamics and the interaction with the immune system.
Our findings have important implications for basic research
studies on mechanisms of resistance to checkpoint blockade and
for clinical translation. Most importantly, given that neutral
evolution, T-cell-dependent immunoediting, and T-cell-
independent immunoediting are sculpting the tumor, it is of
utmost importance to carry out comprehensive genomic and
immunogenomic analyses of pre- and post-treatment samples. As
conventional cancer therapy as well as cancer immunotherapy are
altering the genomic landscape, clones that are resistant to ther-
apy might arise and outcompete other clones. Thus, it is an
imperative to characterize the applied mouse models and the
evolutionary forces driving the tumor in order to dissect the
contribution of individual components on shaping the cancer
genome. Over and above, since MMR deficiency predicts
response to checkpoint blockade in 12 different solid tumor
types45, further studies using genetically engineered mouse
models46 could help to identify molecular determinants that
make not only CRC tumors sensitive to immune checkpoint
blockade, but possibly also other tumor types.
Finally, our results have important implications also for clinical
research. Given the fact that some cancers including CRC, sto-
mach, lung, and bladder are dominated by neutral evolution34, it
will be important to study tumors over time to determine the
impact of the immunological selection following checkpoint
blockade. Theoretically, neutral evolution generates greater tumor
heterogeneity and hence, may facilitate adaptation after the
initiation of immunotherapy. However, investigating evolutionary
dynamics within human cancer is challenging since longitudinal
observations are unfeasible and both, the genetic and immune
landscape of cancer, are highly dynamic and interwoven8. Use of
new technologies such as single-cell sequencing, as well as mul-
tiregion sequencing and higher sequencing depth together with
improved computational methods, as recently shown47, will
provide better understanding of the relationship between the
clonal architecture of a tumor and the antitumor response of the
immune system. In this context, advances in organoid and gene-
editing technologies will open new avenues of research and ulti-
mately lead to the development of effective strategies for precision
immuno-oncology.
In summary, we demonstrated that neutral evolution is the
major force sculpting the tumor during progression and that
checkpoint blockade effectively enforces T-cell-dependent
immunoselective pressure in mouse models of CRC. Our study
investigates another layer of complexity of the tumor evolution
and the dynamic nature of clonal selection driven by immuno-
logical and non-immunological mechanisms. An improved
understanding of how the immune system affects tumor pro-
gression will be fundamental to improving response to immu-
notherapies and combating resistance, but will require
comprehensive genomic and immunogenomic analyses of both
mouse models and human samples.
Methods
Cell culture. The MC38 cell line, derived from methylcholanthrene-induced
C57BL6 murine colon adenocarcinoma cells was maintained in DMEM supple-
mented with 10% FBS, 1mM L-Glutamine, and Penicillin (100 µ/ml)–Streptomycin
(0.1 mg/ml), at 37 °C under 5% CO2 pressure. The CT26.WT cell line, derived
from N-nitroso-N-methylurethane-induced BALB/c (H-2d) undifferentiated colon
carcinoma was maintained in RPMI1640 supplemented with 10% FBS, 1mM L-
Glutamine, and Penicillin (100 µ/ml)–Streptomycin (0.1 mg/ml), at 37 °C under 5%
CO2 pressure. The MC38 cell line was kindly provided by Maximillian Waldner,
University of Erlangen, Germany. The CT26 WT cell line was provided by TRON.
Cell lines were tested negative for mycoplasma (GATC, Konstanz, Germany). All
media components were obtained from Sigma-Aldrich. For implantation cells were
washed with PBS (Sigma-Aldrich), mildly trypsinized, further washed in PBS, and
checked for viability before finally being dissolved in PBS at the desired densities.
Mouse experiments. Wild-type C57BL/6N mice RAG1−/− (B6.129S7-RAG1tm1-
Mom/J) mice were purchased from Charles River. Mice were maintained under SPF
conditions. All animal experiments were performed in accordance with the Aus-
trian “Tierversuchsgesetz” (BGBI. Nr.501/1989 i.d.g.F. and BMWF-66.011/0061-II/
3b/2013) and were approved by the “Bundesministerium für Wissenschaft und
Forschung” (bm:wf).
A total of 5 × 104 MC38 colon carcinoma cells were injected subcutaneously (s.
c.) into the left flank of 8- to 12-week-old female wild-type or RAG1−/− mice.
Tumor growth was monitored three times per week by measuring tumor length
and width. Tumor volume was calculated according to the following equation:
½(length × width2). Each excised tumor was randomly divided in three pieces and
used for either DNA or RNA isolation or for FACS analysis. For survival analysis,
mice with tumors greater than the length limit of 15 mm were killed and counted
as dead.
Wild-type C57Bl/6N mice were injected s.c. with 5 × 105 MC38 cells and
administered with 0.5 mg of an anti-mouse PD-L1 (Clone10F.9G2; BE0101)
antibody or corresponding IgG2b (LTF-2; BE0090) control antibody (all from
BioXCell, USA) i.p. every 3–4 days starting from day 1 of the MC38 challenge.
Tumor growth was monitored as described above. DNA and RNA isolations were
done from complete excised tumors.
Wild-type BALB/c mice were injected s.c. with 5 × 105 CT cells and
administered with 0.5 mg of an anti-mouse PD-L1 (Clone10F.9G2; BE0101) or
corresponding IgG2b (LTF-2; BE0090) control antibody (all from BioXCell, USA)
every 3–4 days starting from day 1 of CT26 challenge. Tumor growth was
monitored as described above. DNA and RNA isolations were performed from
complete excised tumors.
Immunophenotyping. Mononuclear infiltrating cells were isolated from both
subcutaneous tumors and skin tissue at the indicated time points48. In brief, tumor
and skin tissues from killed mice were prepared by mechanical disruption followed
by digestion for 45 min with collagenase D (2.5 mg/ml; Roche, 11088858001) and
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DNase I (1 mg/ml; Roche, 11284932001) at 37 °C. For skin tissue Liberase (5 mg/
ml; Roche, 5401020001) was added to the above described digestion mix. Digested
tissues were incubated 5 min at 37 °C with EDTA (0.5 M) to prevent DC/T-cell
aggregates and mashed through a 100-µm filter and a 40-µm filter. Cells were
washed, and resuspended in PBS+2% FCS.
Tumor and skin-infiltrating immune cells were incubated with FcR Block (BD
Biosciences, 553142) to prevent nonspecific antibody binding before staining with
appropriate surface antibodies for 30 min at 4 °C, washed with PBS+2% FCS, and
used for FACS analysis. For intracellular cytokine staining, cells were stimulated
with 50 ng/ml Phorbol 12,13-dibutyrate (PDBu, Sigma, P1269), 500 ng ionomycin
(Sigma, I0634), and GolgiPlug (BD Biosciences, 555029) for 4–5 h. After fixation
with the FoxP3 staining buffer set (eBiosciences, 00-5523) for at least 30 min at 4 °
C, cells were permeabilized with the fixation/permeabilization buffer (eBiosciences,
00-5523) and incubated with FcR Block (BD Biosciences, 553142) before staining
with specific cell surface or intracellular marker antibodies. Data acquisition was
performed on a LSR Fortessa cell analyzer (Becton Dickinson). Data analysis was
conducted using the Flowlogic software (eBioscience, version 1.6.0_35).
The following antibodies were used for flow cytometry at a concentration of
1:200 with exceptions marked in the list: CD4-V500 (BD, 560783), CD45-V500
(BD, 561487), CD8a-PerCP Cy5.5 (eBiosciences, 45-0081-82), CD3-PE
(eBiosciences, 12-0031-83), CD11c-PerCP Cy5.5 (eBiosciences, 45-0114-80),
CD11b-PE (BD, 557397, 1:500), CD45-APC (eBiosciences, 17-0451-81), F4/80-PE-
Cy7 (BioLegend, 123113), CD49b-FITC- (eBiosciences, 11-5971-81), Foxp3-FITC
(eBiosciences, 11-5773-82, 1:100), IFNγ-PE-Cy7 (eBiosciences, 25-7311-82),
CD25-bv421 (BioLegend, 102034), Gr-1-APC (eBiosciences, 17-5931-81, 1:500),
MHCII-bv421 (BD, 561105).
Exome- and RNA sequencing. Library preparations and sequencing was per-
formed at the Innsbruck Medical University Sequencing CF according to the fol-
lowing procedures. Whole-exome sequencing of the tumor, skin, and MC38 cell
samples was performed with exome capture using SureSelectXT Mouse All Exon
capture probes (Agilent Technologies Österreich GmbH, Vienna, Austria) followed
by sequencing with the Ion Proton System (Ion Torrent, Thermo Fisher Scientific).
For RNA sequencing, total RNA was extracted, quality validated with the Agilent
Bioanalyzer, and submitted to QuantSeq 3′ mRNA-Seq library preparation, fol-
lowing the manufacturer’s instructions (Lexogen, Vienna Biocenter, Austria).
Resulting libraries were sequenced with the Ion ProtonTM System.
Exome-sequencing data analysis. The sequencing reads were preprocessed
through a quality control pipeline where they were trimmed to a maximum read
length of 180 base pairs in addition to trimming the first nine bases with Trim-
momatic49. The trimmed reads were then aligned to the mm10 reference genome
using bwa-mem50. Picard was used to clean and sort the aligned bam files and to
remove duplicate reads (http://broadinstitute.github.io/picard) and GATK for indel
realignment and base quality score recalibration. Somatic point mutations were
identified with Mutect51 by comparing each tumor sample with the two skin
samples and taking the intersection of the mutations. Insertions/deletions were
called with Strelka52 in the same way. Mutations were filtered so that only muta-
tions with at least 10 alternative reads were considered. The somatic mutations
were annotated using the Ensembl Variant Effect Predictor tool53. Somatic copy
number estimations were derived from the exome-sequencing data using EXCA-
VATOR54 by calculating log2 ratios between the read depth of the tumor and two
germline skin samples using the “pool” mode. The estimated log2 ratios were then
segmented by their novel heterogeneous shifting level model. The copy number
alterations (CNAs) identified using exome-sequencing data were concordant to
those in the same samples by using Affymetrix SNP Array. LOH events were
derived using VarScan2. MutationalPatterns (https://doi.org/10.1101/071761) was
used to infer the contribution of published mutational signatures19.
SNP arrays. Genome-wide copy number profiles of two wild-type samples (day 23
and day 46), two RAG1−/− samples (day 13 and day 23), all six anti-PD-L1 and
IgG2b samples, MC38 and skin germline DNA were obtained using the Affymetrix
Mouse Diversity Array. The genotyping analyses were carried out at Eurofins
Genomics (Ebersberg, Germany) using the Affymetrix Mouse Diversity Array. The
SNP arrays were processed, quantile-normalized, and median-polished using the
Aroma Affymetrix CRMAv2 algorithm55 together with 351 publically available
Mouse Diversity Genotyping Array CEL files which were downloaded from the
Center for Genome Dynamics at The Jackson Laboratory (http://cgd.jax.org/
datasets/diversityarray/CELfiles.shtml). CNAs for each probe were computed as
log2-ratios between the probe signal intensities of each sample and the reference
skin sample and then those ratios were segmented using the circular binary seg-
mentation algorithm implemented in the R package DNAcopy56.
Tumor heterogeneity. Normal contamination estimates were calculated using the
homozygous point mutations in the cell line MC38. Considering that the purity of
the cell line is 1, we checked the VAF of the homozygous mutations in MC38 in all
the samples together with the estimated copy numbers of the corresponding region.
The expected VAF of these mutations should be 1 in all samples assuming that
there is no normal contamination and no new mutations appearing in the mouse
samples at the same genomic position. As an estimate of the purity of the tumor,
we took the mean of the VAF of those mutations found in a diploid region. These
estimates were used to correct the mutation VAFs or copy number estimates in the
rest of the analyses.
The CCF of each mutation was calculated by integrating the above mentioned
purity estimates and the copy numbers from EXCAVATOR, using the approach of
McGranahan et al. In brief, the VAF of each mutations, given the CCF, can be
calculated as follows:
VAF CCFð Þ ¼ p  CCF= CNn  1 pð Þ þ p  CNt½ 
where p is the tumor purity, and CNt and CNn are the tumor and the normal locus
specific copy number. The expected number of mutated reads x follows a binomial
distribution with a total depth of N, such that the probability of a given CCF can be
estimated using P(CCF) = binom(x|N, VAF(CCF)). CCF values can then be
calculated over a uniform grid of 100 CCF values (0.01,1) and then normalized to
obtain a posterior distribution. Using this approach, mutations were classified as
clonal if the 95% CCF confidence interval overlapped 1, and subclonal otherwise.
Subclonal clusters of mutations were identified using a previously described
statistical modeling of the distribution of clonal and subclonal mutations by a
Bayesian Dirichlet process57–59.
Tumor heterogeneity of the mutational data from human melanoma patients
was analyzed using the allele-specific CNAs in addition to the VAF and purity that
was provided with the data. For each mutation, the observed mutation copy
number, nmut (the fraction of tumor cells carrying a given mutation multiplied by
the number of chromosomal copies at that locus) was calculated as:
nmut ¼ VAF 1p pCNt þ CNn 1 pð Þ½ 
where VAF is the variant allele frequency of the mutation, p is the tumor purity,
and CNt and CNn are the tumor and the normal locus specific copy number. As
mutations that are present of multiple chromosomal copies will have a mutation
copy number higher than 1, we determined the number of chromosomes that the
mutations is residing on. This was done so that for all mutations in amplified
regions with a copy number of CNt, the observed fraction of mutated reads is
compared with the expected fraction of mutated reads resulting from a mutation
present on 1,2,3,…,CNt copies, considering a binomial distribution. The CCF was
then calculated as the mutation copy number divided by the value of C with the
maximum likelihood. Mutations were defined as clonal if the CCF was > 0.95, and
subclonal otherwise.
RNA-seq data analysis. The sequencing reads were first preprocessed through a
quality control pipeline consisting of adapter removal with Cutadapt (http://dx.doi.
org/10.14806/ej.17.1.200) and quality trimming with Trimmomatic49 to remove
bases with bad quality scores and reads shorter than 22 nucleotides. The quality
trimmed reads were then mapped to the mm10 reference genome using a two-step
alignment method; alignment with STAR60 followed by alignment of the
unmapped reads with Bowtie2. From the reads that mapped to multiple locations
in the genome only the primary alignment was retained. Reads that mapped to
ribosomal RNA locations in the genome were removed from further analysis using
the split_bam.py script from the quality control package RSeQC61. Gene-specific
read counts were calculated using HTSeq-count62. The R package DESeq263 was
used for differential expression analysis. The p-values were adjusted for multiple
testing based on the false discovery rate using the Benjamini–Hochberg approach.
Neoantigens and CGAs. All possible 8–11 mer mutated peptides generated from
all the nonsynonymous mutations (missense and nonsense) were used as an input
to netMHCpan to predict their binding affinity to the C57BL/6 MHC class I alleles
H-2Kb and H-2Db. Among the candidate antigenic peptides, only the strong
binders with binding affinity < 500 nM, and peptides arising from expressed genes
were retained for further analysis. A mutation was considered expressed if the
normalized counts of the corresponding gene were >5.
The list of CGA was downloaded from the Cancer-Testis database64. Their
expression level was estimated using the normalized counts from DESeq2.
Statistical analysis. For comparison of two sample groups, a two-tailed unpaired
Student’s t-test was performed. Analysis and visualization of Gene Ontology terms
and pathways associated with differentially expressed genes was performed using
ClueGO65. A p-value of <0.05 was considered statistically significant: *p < 0.05;
**p< 0.01; ***p< 0.001.
Data availability. The mouse expression data and the SNP array data were
deposited in the GEO under the accession number GSE93018. The exome
sequencing bam files were deposited in the Sequence Read Archive under the
accession number SRP095725. Mutational data from the melanoma patients39 were
provided by Dr. Antoni Ribas. The authors declare that all the other data sup-
porting the findings of this study are available within the article and its supple-
mentary information files and from the corresponding authors upon reasonable
request.
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